1. The Astrocytic Endothelin System and Amyotrophic Lateral Sclerosis
  2. Target ALS Multicenter Human Postmortem Tissue Core
  3. A Pilot Clinical Trial of Metabotropic Glutamate Receptor 5 (mGluR5) PET Imaging in Amyotrophic Lateral Sclerosis
  4. MRI Imaging of Myelin Injury in ALS Patients

Abnormally increased production of a protein called endothelin by astrocytes may represent a novel therapeutic target in ALS.

I am also the PI for an ALSA-funded clinical trial of mGluR5 PET imaging in ALS – a potential biomarker to assist in ALS diagnosis and for monitoring disease progression, and I am initiating a pilot trial of MRI Imaging to detect myelin injury in ALS patients.

I am the Director of the Target ALS Multicenter Human Postmortem Tissue Core. This program establishes the first multicenter postmortem tissue bank dedicated to ALS research, with defined standard operating procedures for donor recruitment, tissue acquisition, processing, storage, histopathological characterization, and electronic data management and archiving. We also are establishing best practices for collaborative molecular and neuropathological research using postmortem human ALS tissues, and creating a database of validated experimental protocols to foster optimal use and collaboration.